

Keyword Index

A

ABCB7	A076
access to care	B045
acute lymphoblastic leukemia	B025
adherence	B043
adolescent and young adult	PR001, A021
AKT signaling	A079
Alectinib	PR011
ALK-fusion	PR011
alternative lengthening of telomeres	B020
AML	B036
anti-GD2 monoclonal antibody	B055
antigen escape relapse	B052
asparaginase resistance	A067
ATRT	A080

B

B-cell acute lymphoblastic leukemia	A067, B051, B052
B-cell precursor acute lymphoblastic leukemia	B027
BCR-ABL fusion gene	B038
beta-3 adrenergic receptor (β 3 -AR)	A061
bioinformatics	B001
biomarkers	A033, B031
biomarkers for response	A058
BMI1 proto-oncogene, polycomb ring finger	A080
bone morphogenetic protein (bmp) signaling	B005
bone toxicities	B025
brain cancers and sarcoma	B003
brain tumor	B012

Keyword Index

BRCA1	B081
C	
cancer genome	B070
cancer predisposition	PR001, A005, A010, A021, A023, A028, B019, B030
cancer registries	B071
cancer stem cells	PR012, A059
cancer surveillance	A023
cancer treatment and care	B069
CAR T cells	IA015, B047
CAR T-cell therapy	PR010, B052, B053, B059
CDK 4/6	B065
CDK2/9 inhibitor	A066
CDK8	A082
cell free DNA	PR005, A032, A036
cell of origin	A022
cell transformation	A022
cerebrospinal fluid	A044
cGAS-STING	B064
chemoresistance	A054, A066, A074, A079, B001
chemotherapy	B070
childhood cancer	PR002, A008, B071
childhood cancer survivors	PR008, B041, B080
chimeric antigen receptor T cell	B051
chromatin reprogramming	A071
circulating tumor cells	A046, B072
circulating tumor DNA	A039
classifier	B034

Keyword Index

clinical translation	IA003
clonal evolution	B001
cloud-based platform	B068
clusterin	B058
comparative oncology	A038
computational analysis	B068
computational genomics	A010
CRISPR Cas13d	A012
cross-species comparative oncology	B010
ctDNA	IA010, A045, B035
ctDNA sequencing	A034, A035
cytokine	B051
D	
data extraction	B071
dendritic cells	A047
desmoplastic small round cell tumor	A070
development	A022
DICER1	A026
differentiation	B008
diffuse midline gliomas	IA016
digital	B023
DIPG	PR010, B059, B065
disease control rate	B055
disparities	PR007, B037, B043, B045
DNA damage response	A007
DNMT3B	A050
doxorubicin	A069
drug resistance	A072

Keyword Index

drug response	PR003, B017
drug sensitivity profiling	B021
drug testing	B016
E	
early phase clinical trial	B015, B066
environmental factors	A028
ependymoma	B073
epidemiology	PR007, B037
epigenetic	A056, A062, A073, B010
epigenetic targeting	A063
epigenomics	A054, B018
ethnic variation	B038
ETS1	A004
Ewing sarcoma	IA021, A016, A017, A022, A029, A049, A056, A060, A065, B048, B058, B076, A048, A061 B081
EWS/FLI-1	B081
EWS::FLI1 fluctuations	A017
EWSR1	A016
ex vivo models	B021
exomeres	B031
exosomes	A038
extracellular vesicles	B031
EZH2 inhibitor	A051
F	
ferroptosis	A048, A076, A078

Keyword Index

FGF8	A015
filanesib	A060
focal adhesion	A004
functional precision medicine	A068, B016
functional profiling	PR004, B013, B014
fusion oncoprotein	A001
fusion protein	B022, B079
fusion-positive rhabdomyosarcoma	B010
fusions	B004

G

ganglioside GD2	IA015
GD2-SADA	A075
gene expression	B036
gene expression classification	B026
genetic mutations	A028
genetic predisposition	IA003
genetics	A019
genetics and month of birth	A027
genomes	B068
genome-wide association study (GWAS)	B025
genomics	B014, B026
Ghanaian health sector	B042
glioma	A052, B078
group 3 medulloblastoma	A076

H

healthcare transition	PR008, B041
heparin-binding EGF-like growth factor (HB-EGF)/ErbB	B062

Keyword Index

hepatoblastoma	B024
hereditary cancer	A023, A039
high BCR-ABL burden	B039
high-risk neuroblastoma	A075, B055
Hispanic disparities	B046
histones	A073
human bone cell co-cultures	B029
hyperthermia	A064
I	
IL1RAP interleukin 1 receptor accessory protein (IL1RAP)	B053
immune checkpoint inhibitor	A047
immune checkpoints	A046
immune infiltration	B015, B033
immune microenvironment	A064
immune-based innovative treatments	A006
immunogenomics	A037
immunoliposome	A065
immunology	B056
immunotherapy	B049, B054, B060
implementation	A035
in vivo modeling	A007
induction failure	A025
infant acute lymphoblastic leukemia (ALL)	B026
innovative trial designs	IA026
INO80 complex	A014
invasion	A057
iodine	A057

Keyword Index

K

kinases	B004
kinesin	A060
leukemia	A019, B047
leukemia initiation	A002

L

Li-Fraumeni syndrome	IA004, A005, A009, A013
LincRNA	IA021
liquid biopsies	IA010, PR005, PR006, A032, A033, A041, A044, A045, B019, B035 PR010, B059
logic-gated	
longitudinal studies	B056

M

Machine learning	A010, B077
macrophage	IA016, B053, B062
malignant rhabdoid tumors	A006
mechanism	A022
medulloblastoma	A071, A082, B017, B063
metastasis	A031, A049, A063, B008, B076
methylation reprogramming	B057
METTL1	A012
microbiota	A013
microglia	IA016
microprotein	B017
miRNA	A026
missense	B028

Keyword Index

mitogen-activated protein kinase (MAPK)	A015
mitogen-activated protein kinase (MAPK) pathway	B003
model development	B079
models of survivorship care	B080
molecular diagnosis in developing countries	B039
molecular diagnostics	B036
MondoA	A067
mouse model	A006
multi-omic integration	B057
multiomics	A070
multiple symptoms	B040
MYC-driven	A012
MYCN	A053
myeloid leukemia of Down syndrome	A018
N	
nanoparticles	B031
natural killer cell therapy	A078
natural killer cells	PR009, B050
neuroblastoma (NBL)	PR006, PR009, A003, A007, A020, A031, A034, A037, A041, A053, A054, A055, A058, A062, A066, A073, A078, B005, B006, B020, B050, B060, B062, B064, B074
neuroblastoma (NBL) lineage states	B064
NF-κB	A013
nicotinamide adenine dinucleotide (NAD)	A081
nicotinamide phosphoribosyltransferase (Namp1)	A081

Keyword Index

non-metastatic	B073
nucleosome footprints	IA010
NUP98-rearrangement	A019
O	
olaparib	A072
omics	B009
oncogene	B002, B004
oncogenesis	B022
oncogenic collaboration	A002
oncokinase	B022
oncolytic virus	B049
open science	B075
osteosarcoma	A005, A038, A043, B018, B031, B033, B049, B054
P	
pan-cancer	B009
PARP inhibitor	A065
pathology	B023
pathomechanism	B029
patient advocacy	B069
patient informed assays	A045
patient reported outcomes	B066
patient-derived xenograft (PDX) models	PR003
patient-derived xenografts	A058
PAX3-FOXO1	A014
pediatric	PR001, PR011, A021
pediatric acute lymphoblastic leukemia (ALL)	A027, B038

Keyword Index

pediatric acute lymphoblastic leukemia (ALL) molecular epidemiology	B039
pediatric brain tumor	A040
pediatric cancer	A030, A039, B011, B044, B045, B070
pediatric cancer survivors	B040
pediatric fractures	B029
pediatric liver cancer	B072
pediatric precision oncology	IA026
pediatric sarcomas	B061
pediatric solid tumor	PR005, A032, A033, B016, B046
pediatric tumors	A046
personalized combinations	B003
phase 1	B065
phylogeny	A018
plasticity	A055
poverty	PR007, B037
precision medicine	PR004, B007, B009, B012, B013, B014, B021, B030
precision oncology program	A035
preclinical testing	IA026, B007
predictive biomarkers	B018
predisposition	PR002, A008, A011
pretargeted radioimmunotherapy (PRIT)	A075
prognosis	A043
protein regulator of cytokinesis 1 (PRC1)	A080
proteolysis targeting chimera (PROTAC)	A068
proteomic plasma	A043
proteomics	PR003, B019
psychosocial	B043

Keyword Index

R

racial inequities	B042
radiation	A047, B078
radiotherapy	A030
RAS	A053
reactive oxygen species (ROS)	A061
receptor tyrosine kinase	B002
recurrence	B063
regression	A003
remote national access	A034
renal	A011
replication stress	A056
replication timing	B074
resistance	A051, A069, A071
retinoic acid	B005
rhabdoid tumor	A050, A051
rhabdomyosarcoma	A001, A014, A063, A072, A079, A081, B008
RNA polymerase II	B081
RNA sequencing (RNA-seq)	A040, B014, B015, B027, B077
rural-urban differences	B040

S

sarcoma	A009, A064, A070, A074, B023, B034, B079
scholastic outcomes	B044
seasonality and cytogenetics in ALL	A027
second malignant neoplasm	IA004

Keyword Index

secondary malignancy	A030
signal transduction	B002
single cell DNA sequencing (scDNA-seq)	B074
single cell multiomics	B061
single cell	A052, B075
single-cell RNA sequencing (scRNA-seq)	A009, A018, A025, A044, B006, B047
small interfering RNA (SiRNA)	A068
SMARCB1	B028
SMARCB1 deficient	A069
social determinants	PR008, B041
socioeconomic status	B042
soft tissue sarcoma	PR012, A059
spatial transcriptomics	A052, B033
Spt-Ada-Gcn5 acetyltransferase (SAGA)	A062
STAG2	A029
stem cell modeling	A020
stimulator of interferon genes (STING)	B054
subtype classification	B027
supermeres	B031
surgery	PR009, B050
survival	B073
survivorship	B044
survivorship care	B080
T	
T cell	A037, B060
T cell exhaustion	B058
T cell leukaemia	A025
T cell therapy	IA021

Keyword Index

tandem myeloablative therapy	B020
targeted therapy	PR004, B013
telomere	A024
telomeric repeat binding factor 1 (TERF1)	A024
temozolomide	A072
TENSIN3 (TNS3)	A004
therapy resistance	PR012, A059
therapy-related cancer	IA004
toxicant	A029
transcription	A016, B078
transcription dysregulation	A001
transcriptomics	B034
translation	A082, B069
tumor classification	B077
tumor evolution	PR006, A041
tumor heterogeneity	B024
tumor immune environment	B056, B057
tumor plasticity	A017
tumor suppressor	B028
tumor-associated macrophages	B061
tumor-educated platelets (TEPs)	A040
tumour evolution	A036
tumour microenvironment	B063
U	
underserved communities	B046
V	
vascular invasion	B072

Keyword Index

W

whole-genome sequencing (WGS)	PR001, A011, A021, B011, B030
Wilms tumor	PR002, A008, A015
Wnt family member 5A (Wnt5a)	A049
Wnt signal transduction pathway	B024

Y

YAP/TAZ	A055
---------	------

Z

zebrafish	A002, A003, A026, A031, A057, B007
-----------	---------------------------------------